Cenobamate

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Cenobamate

Examples of brand names: Ontozry [EU/DE]

ATC code: N03AX25

Main use (for orientation): Epilepsy

Documented research summary

Series involving several antiseizure medicines do not isolate a CBD–cenobamate effect. Simultaneous changes to several medicines do not provide unambiguous evidence for an individual pair.

Uncertainties and limitations

Shared CYP/UGT pathways do not establish a directional quantitative effect.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Cenobamate: CYP2C19 inhibition, CYP3A/2B6 induction, glucuronidation; QT shortening.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Cenobamate, active substance.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0056]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: XCOPRI TITRATION PACK (CENOBAMATE) KIT XCOPRI (CENOBAMATE) TABLET, FILM COATED XCOPRI MAINTENANCE PACK (CENOBAMATE) KIT XCOPRI (CENOBAMATE) TABLET [SK LIFE SCIENCE, INC.] [CA_L_D0056]

Source role [CA_P_40536598]: Scope distinction / context

Statement supported: Retrospective LGS series with co-medication, not an isolated CBD–cenobamate pharmacokinetic experiment.

Source: Cenobamate for Adjunctive Treatment in Adult and Pediatric Patients with Refractory Lennox-Gastaut Syndrome: A Retrospective Chart Review. [CA_P_40536598]

Source role [CA_P_42358368]: Scope distinction / context

Statement supported: Dravet cases involving several medicines; no isolated effect of the pair.

Source: Cenobamate in pediatric Dravet syndrome: two responder cases highlighting the limits of simple "sodium-channel blocker" labeling. [CA_P_42358368]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[CA_L_D0056] XCOPRI TITRATION PACK (CENOBAMATE) KIT XCOPRI (CENOBAMATE) TABLET, FILM COATED XCOPRI MAINTENANCE PACK (CENOBAMATE) KIT XCOPRI (CENOBAMATE) TABLET [SK LIFE SCIENCE, INC.]

Original source / bibliographic reference

Authors: SK Life Science, Inc.

Year: 2025

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_40536598] Cenobamate for Adjunctive Treatment in Adult and Pediatric Patients with Refractory Lennox-Gastaut Syndrome: A Retrospective Chart Review.

Original source / bibliographic reference

Authors: Keough K, Romick A.

Year: 2025

Source type: Journal Article; case-report

DOI: 10.1007/s40120-025-00779-x

PMID: 40536598

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[CA_P_42358368] Cenobamate in pediatric Dravet syndrome: two responder cases highlighting the limits of simple "sodium-channel blocker" labeling.

Original source / bibliographic reference

Authors: Makridis KL, Laux LC, Kaindl AM.

Year: 2026

Source type: Journal Article

DOI: 10.3389/fphar.2026.1809113

PMID: 42358368

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility